Month: July 2016

• July 21, 2016
• Imaging & mpMRI

Hormone Therapy Affects Mental Function

Androgen deprivation therapy (ADT) is a treatment for prostate cancer that has spread outside the gland. It is also called hormone therapy or chemical castration. The purpose of ADT is to reduce the production of male hormones, especially testosterone, which has the effect of temporarily halting the ability of prostate cancer cells to multiply and keep reading

• July 19, 2016
• Imaging & mpMRI

Updated Focal Therapy Data From NIH

Dr. Peter Pinto is one of the most respected urologic researchers in America. He is the Head of the Prostate Cancer Section of the Urologic Oncology Branch of the Center for Cancer Research (National Cancer Institute/National Institutes of Health). That’s a very long formal title for a man who is humble, personable and good-natured. His keep reading

• July 11, 2016
• Biopsy

A Critique of Transperineal Biopsy Study On MRI/Ultrasound Fusion Guidance

I read a study on the accuracy of prostate MRI for predicting that no prostate cancer (PCa) is present. This is called the negative predictive value (NPV), and the authors make a great point in their introduction: The reliability of a negative MRI is a key clinical metric – if the MRI is reported as keep reading

• July 4, 2016
• Imaging & mpMRI

MRI/Ultrasound Fusion: Not Ready for Prime Time

When an authoritative person weighs in on a topic, we sit up and take notice. Dr. Ardeshir (Art) Rastinehead is an Interventional Urologic Oncologist and he is impressively credentialed. His experience includes fellowship training at the National Cancer Institute (NIH) with. Peter A. Pinto and Bradford J. Wood, pioneers in the research and development of keep reading